They evenly distribute throughout the normal myocardium in proportion to the blood flow, depicting the dead/ischemic tissues as black spot. problem. Although cardiac scintigraphy using radioactive perfusion tracers is used in the assessment of myocardial viability, searching for diagnostic imaging brokers with authentic necrosis avidity is usually pursued. Therefore, a comparative study on the biological profiles of the necrosis avid123I-Hyp and the commercially available99mTc-Sestamibi was conducted and the results are demonstrated. Cholelithiasis or gallstone disease may cause gallbladder inflammation, infection and other severe complications. While studying the mechanisms underlying the necrosis avidity of Hyp and derivatives, their naturally occurring fluorophore house was exploited for targeting cholesterol as a main component of gallstones. The usefulness of Hyp as an optical imaging agent for cholelithiasis was analyzed and the results are offered. Multiple uses of automatic contrast injectors may reduce costs and save resources. However, cross-contaminations with blood-borne pathogens of infectious diseases may occur. We developed a radioactive method for security evaluation of a new replaceable patient-delivery system. By mimicking pathogens with a radiotracer, we assessed the feasibility of using the system repeatedly without septic risks. This overview is deemed to be interesting to those involved in the related fields for translational research. Keywords:Translational medical research, Malignancy treatment, OncoCiDia, Vascular disrupting agent, Hypericin, Myocardial infarction, Gallstone, Transflux Core tip:Translational medicine converts scientific discovery into clinical applications. Radiopharmacy has played a multidisciplinary role. Based on unique necrosis avidity, OncoCiDia presents a generic approach for management of cancers, on which recent results on its optimization are summarized. Myocardial infarction is usually a clinical problem. A comparative study between infarct avid iodine-131 labeled-hypericin and commercial99mTc-Sestamibi is usually offered. Cholelithiasis may cause biliary complications. The usefulness of Hyp as an optical imaging agent for cholelithiasis is usually demonstrated. Multiple uses of automatic contrast injectors may reduce costs but can cause cross-contaminations. We developed a radioactive method for security evaluation of a new replaceable patient-delivery system. == INTRODUCTION == Translational medicine refers to the GANT 58 creativity of joining knowledge from bench to bedside or from laboratory experiments to clinical trials for generating new drugs, devices, diagnostic and therapeutic options for patients. Hence, translational research is identified as a crucial interface between basic science and clinical medicine. It intends to discover better ways to solve actual practical problems enhancing human health SQSTM1 and well-being. Another current pattern in translational medical research is to cross diagnosis and therapy into a combined approach as newly termed a theragnostic modality. In the area of malignancy therapeutics, transforming basic research results into clinical practice is becoming progressively important. Cancer is one of the leading causes of mortality worldwide and little progress has been achieved in treating most of the solid tumors, which could be resistant to common therapies. Based on necrosis-avidity, OncoCiDia is usually a generic and unconventional theragnostic strategy recently launched as a complementary modality to improve malignancy treatability[1,2]. Unlike other malignancy therapies directly attacking multimutant and refractory malignancy cells, OncoCiDia may selectively treat solid malignancies by massively necrotizing the tumors plus radioactively cleansing their microenvironments, in the mean time the tumors under treatment can be visualized by nuclear scintigraphy. Thus, a dedicated acronym OncoCiDia is created to portray this malignancy (Onco) management approach with both tumoricidal (Ci) and diagnostic (Dia) effects. It consists of two sequential complementary treatments involving the intravenous application of a vascular disrupting agent (VDA) followed by systemic targeted radiotherapy (STR) using a potent necrosis-avid compound iodine-131 labeled-monoiodohypericin (131I-Hyp). Furthermore, to GANT 58 make this novel anticancer strategy clinically relevant, optimizations of the procedures for labeling, purification and formulation of the radioiodinated GANT 58 hypericin (Hyp) have been performed and the outcomes are summarized.
They evenly distribute throughout the normal myocardium in proportion to the blood flow, depicting the dead/ischemic tissues as black spot